The global mesenchymal stem cell market is expected to grow at a CAGR of around 7.1% from 2020 to 2027 and expected to reach the market value of around US$ 2,600.5 Mn by 2027.
Tissue or 'adult' stem cells include mesenchymal stem cells (MSCs). They are ‘multipotent,' which means they can produce more than one type of specialized cell in the body, but not all of them. MSCs are responsible for the production of the various specialized cells found in skeletal tissues. They can differentiate or specialize into cartilage cells (chondrocytes), bone cells (osteoblasts), and fat cells, for example. Each of these specialized cells has its own distinct shape, structure, and function, and each belongs to a specific tissue. Furthermore, mesenchymal stem cells were isolated for the first time from bone marrow and later from cord cells, adipose tissue, and molar cells. MSCs are smaller in size and more difficult to see in histological sections. Mesenchyme is a group of mesenchymal stem cells that are widely distributed throughout the body. Mesenchymal cells can divide into numerous specialized cells and grow in vitro or in vivo.
Big calls for "Bioengineering solutions" to fuel the functions of mesenchymal stem cells (MSCs)
According to the American Association for the Advancement of Science report, clinical trials to date show that MSCs can be safely infused in high doses and show promising results in some clinical indications. Quality control protocols to standardize MSC product potency may help reduce the risk of clinical failure, but they are unlikely to completely resolve the problem, as MSCs' innate function is not always therapeutically sufficient for disease treatment. Simple alternative bioengineering strategies that can boost the innate function of MSCs, regardless of cryopreservation, passage number, donor and tissue source, should be investigated to maximize clinical potency while preserving ease of use. Furthermore, bioengineering can be a powerful platform for translating new insights gained from a fundamental understanding of MSC behavior following infusion into more effective therapies.
Rising prevalence of cancer incidences have gained significant attention for the global mesenchymal stem cells (MSCs) market
Tumor microenvironment interacts with tumor cells, creating an environment that can either contribute to or suppress tumor development. Among the cells that play a role in the tumor microenvironment, mesenchymal stem cells (MSCs) have been shown to be capable of orchestrating the fate of tumor cells, attracting interest in the field. MSCs have been thought to have dual-bladed effects, implying either tumorigenic or anti-tumor activity. Clinical studies, on the other hand, have revealed that MSCs have a promising potential for treating human cancer cells. Among the advantageous properties of MSCs is their natural tumor-trophic migration ability, which allows for drug delivery and, thus, targeted treatment to detach tumor and metastatic cells. Furthermore, because of their easily implemented characteristics, these cells have been the target of engineering approaches in order to obtain the desired expression of anti-angiogenic, anti-proliferative, and pro-apoptotic properties, depending on the tumor type.
MSCs possess clinical effects for stroke treatment and brain repair in patient group bolster the growth of the global market
According to the American Heart Association, Inc., mesenchymal stem cells (MSC) have unique properties that make them an intriguing tool for studying brain repair after ischemic stroke. They have the ability to reduce overall inflammation, thereby removing the potentially toxic environment that could be causing NSC death, as well as support NSC survival and function through the secretion of various neurotrophic factors. To date, numerous preclinical studies and clinical trials have demonstrated the efficacy of MSC therapy in stroke preclinical studies and the safety of MSC treatment in clinical trials..
The global mesenchymal stem cell market is segmented based on product type and application. By product type, the market is segmented as human MSCs, mouse MSCs, rat MSCs, and others. By application, the market is segregated as drug discovery and development, injuries, cardiovascular and myocardial infarction, and others.
Mouse MSCs are expected to dominate the global mesenchymal stem cells (MSCs) market by product type. Because of segmental growth, research and development activities for the mouse as a medium are increasing. The cardiovascular and myocardial infarction application segment is expected to hold an all-time high market share for the global mesenchymal stem cells (MSCs) market. This is due to the high prevalence of stroke cases observed globally among the population base. This is one of the most important factors that contribute to segmental growth.
North America is expected to dominate the global market for mesenchymal stem cells (MSCs). This is due to the rapid growth of technological innovations, high disposable incomes, and well-equipped healthcare centers, all of which will contribute to the growth and development of the MSCs market. Furthermore, high R&D expenditure, the availability of advanced research facilities and skilled professionals, and government initiatives all contribute to the global market's growth.
Asia Pacific, on the other hand, is expected to have the fastest growing CAGR in the coming years. Asia is expected to grow rapidly in the global mesenchymal stem cell market over the next five years. China and India are expected to be the Asia-Pacific region's fastest growing mesenchymal stem cell markets. The large pool of patients and rising government funding and support are two key driving forces for the mesenchymal stem cell market in emerging countries. Furthermore, due to increased R&D budgets in Japan, China, and India, the Asia Pacific market is expected to grow at a rapid CAGR during the forecast period.
In addition, Europe is expected to have the second largest market share in the coming years. This is due to the rapid growth of technological innovations, high disposable incomes, and well-equipped healthcare facilities, all of which will contribute to the growth and development of the MSCs market. The implantation of new mesenchymal stem cells in cancer patients is expected to boost MSC market growth in this region.
The prominent players of the global mesenchymal stem cells (MSCs) market involve R&D Systems, Inc., Cell Applications, Inc., Axol Bioscience, Cyagen Biosciences, Cytori Therapeutics, Inc., STEMCELL Technologies Inc., BrainStorm Cell Therapeutics Inc., Stemedica Cell Technologies, Inc., Celprogen, Inc., and among others
Market By Product Type
Market By Application
Drug discovery and development
Cardiovascular and myocardial infarction
Market By Geography
• Rest of Europe
• South Korea
• Rest of Asia-Pacific
• Rest of Latin America
Middle East & Africa
• South Africa
• Rest of Middle East & Africa
Mesenchymal stem cells market is expected to reach a market value of around US$ 2,600.5 Mn by 2027.
The mesenchymal stem cells market is expected to grow at a CAGR of around 7.1% from 2020 to 2027.
Based on product type, mouse MSCs segment is the leading segment in the overall market.
Rising prevalence of cancer incidences is one of the prominent factors that drive the demand for mesenchymal stem cells market.
R&D Systems, Inc., Cell Applications, Inc., Axol Bioscience, Cyagen Biosciences, Cytori Therapeutics, Inc., STEMCELL Technologies Inc., BrainStorm Cell Therapeutics Inc., Stemedica Cell Technologies, Inc., Celprogen, Inc., and among others.
North America is anticipated to grab the highest market share in the regional market
Asia Pacific is expected to be the fastest growing market in the forthcoming years